Prime-time for LncRNA signatures in acute myeloid leukemia?

Long non-coding RNA (lncRNA) signatures have emerged as important prognostic biomarkers in acute myeloid leukemia (AML), stratifying patients into high-risk and low-risk groups and thus providing valuable insights for personalized treatment strategies. The development of these signatures often involves comprehensive bioinformatics analyses, employing various statistical methods to ensure robustness and accuracy. Nevertheless, many reports are flawed by the presence of specific biases and/or incompleteness. Here we performed a comprehensive review of recently identified prognostic lncRNA signatures in AML, including our own report on a 69-lncRNA signature predicting relapse-free survival in pediatric acute myeloid leukemia. Next to their predictive impact we provide insights into their strengths and shortcomings.